GLOW 70mg Pen Blend: GHK-Cu, BPC-157 & TB-500 Rationale
This page covers the blend itself: why GHK-Cu, BPC-157, and TB-500 appear together, what each contributes to the pathway hypothesis, how a fixed-ratio blend differs from a single-compound route, and where the published evidence stops.
Update History ▾
July 15, 2026: Corrected the storage FAQ (body, visible FAQ, and FAQPage schema) to prefilled-pen handling — store at 2–8°C, no reconstitution — replacing obsolete lyophilised-vial instructions.
April 22, 2026: Initial publication for the GLOW blend rationale
The GLOW 70mg Pen is best read as a pathway stack, not a single compound. The logic is clear: GHK-Cu 50mg for collagen and copper-enzyme signalling, BPC-157 10mg for angiogenic repair models, and TB-500 10mg for cell migration and inflammation-modulation work in preclinical settings. The literature covers each component separately; there is no trial evidence for the three-compound combination. If the research question is about one compound, the GHK-Cu research page, the BPC-157 reference, and the TB-500 reference are the cleaner paths.
What GLOW 70mg Pen Actually Is
GLOW is not a generic skin-peptide label. It is a specific three-compound prefilled pen format made up of GHK-Cu 50mg, BPC-157 10mg, and TB-500 10mg. The reason it reads differently from a single-compound reference is that it is really describing a pathway stack, not one isolated molecule.
That matters because the strongest reading of this page is not “what is the product,” but “what is the rationale for putting these three compounds together?” The answer is that each compound is used to represent a different part of a tissue-remodelling sequence: matrix production, vascular support, and cellular migration.
Why the Three Compounds Are Paired
| Compound | Amount | Main Research Role | How It Fits the Blend |
|---|---|---|---|
| GHK-Cu | 50mg | Collagen and extracellular-matrix signalling | Acts as the core copper-peptide layer |
| BPC-157 | 10mg | Angiogenesis and repair signalling in preclinical work | Adds the vascular-support hypothesis |
| TB-500 | 10mg | Cell migration and inflammation-modulation models | Rounds out the migration / remodelling layer |
The blend rationale is the same logic already referenced on the GHK-Cu Dubai research page: GHK-Cu supports collagen and copper-enzyme pathways, BPC-157 is commonly discussed around angiogenic repair models, and TB-500 is discussed around actin dynamics and cell migration. That is a research hypothesis stack, not a therapeutic claim.
Blend vs Standalone GHK-Cu
The cleanest comparison here is not between GLOW and another blend. It is between GLOW and a standalone GHK-Cu route. Isolating the copper peptide keeps one variable in play, which makes it the better reference when a lab wants single-compound clarity. GLOW fixes three compounds at a set ratio, so any observed result cannot be attributed to one of them — that is the structural trade-off of a blend, independent of any claim about the compounds themselves.
| Route | What It Prioritises | Attribution |
|---|---|---|
| Standalone GHK-Cu | Single-compound copper-peptide route | One variable; result attributable |
| GLOW 70mg Pen | Three-compound matrix / angiogenesis / migration blend | Fixed ratio; result not attributable |
Where the Evidence Stops
Each component of the GLOW blend has its own preclinical literature. The combination does not. No published trial evaluates GHK-Cu, BPC-157 and TB-500 administered together at this or any other ratio, which means three things a reader should hold onto:
- The ratio is a formulation choice, not a result derived from comparative data.
- Interaction effects are unknown — the components have not been studied for additive, synergistic, or antagonistic behaviour with each other.
- Attribution is impossible in a fixed blend: any observed outcome could belong to any of the three, or to the combination.
That is the honest position on a multi-compound research blend. The component references linked throughout this page are where the actual published data sits.
Storage & Handling Notes
The current handling notes are consistent with a prefilled pen workflow: store the unopened pen at 2–8°C, do not freeze, protect it from direct light, and remove the dispensing needle between uses. No bacteriostatic water or reconstitution step is needed.
The full mixing logic is better handled in the bacteriostatic water guide. The GHK-specific research context is covered in the GHK-Cu Dubai article.
GLOW 70mg Pen is a prefilled FlexiPen research blend containing GHK-Cu 50mg, BPC-157 10mg, and TB-500 10mg.
The pairing is a pathway-stack idea: GHK-Cu for collagen and extracellular-matrix signalling, BPC-157 for angiogenic repair models, and TB-500 for cell migration and inflammation-modulation work in preclinical settings.
A blend fixes the ratio between three compounds, so any observed effect cannot be attributed to one of them. A single-compound route isolates the variable. That is why the standalone GHK-Cu literature is the cleaner reference when the research question is about the copper peptide itself.
No. The published literature covers GHK-Cu, BPC-157 and TB-500 individually. There is no trial evidence for the three-compound combination, so the pairing is a pathway hypothesis rather than a demonstrated synergy.
The standalone GHK-Cu page isolates the copper peptide only and is the cleaner choice when a lab wants a single-compound route. GLOW layers GHK-Cu with BPC-157 and TB-500 in a multi-pathway blend.
GLOW is a prefilled FlexiPen, so no reconstitution is needed. Store the unopened pen at 2–8°C, do not freeze, protect it from direct light, and remove the dispensing needle between uses.
Yes. The page uses the site’s UAE research-use framing and is not presented as a human or veterinary product.
How We Evaluated This Guide
This page combines the published literature for each blend component, the existing GHK-Cu research article, and the site’s own handling and compliance pages. The emphasis is on what the blend is designed to represent, how it differs from a standalone GHK-Cu route, and where the combination evidence stops. Read our editorial policy →
- Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343–346.
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987.
- Ehrlich HP, Hazard SW. BPC-157 angiogenesis and repair-signalling context. J Invest Surg. 2010.
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4 as a regulator of cell proliferation and differentiation. Trends Cell Biol. 2005;15(10):503–508.